Overview

Study Evaluating Venlafaxine ER in Recurrent Depression

Status:
Completed

Trial end date:
2005-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression

Phase:

Phase 4

Details

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Treatments:

Venlafaxine Hydrochloride